Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery

BJU International

Volumn 115, Issue 3, 2015, Pages 419-429

  Badani, Ketan K ^a   Thompson, Darby J ^c,i   Brown, Gordon ^c   Holmes, Daniel ^c   Kella, Naveen ^d   Albala, David ^b   Singh, Amar ^e,f   Buerki, Christine ^j   Davicioni, Elai ^j   Hornberger, John ^g,h  

^a NewYork Presbyterian Hospital   (United States)

^b Assoc Medical Professionals   (United States)

^c Delaware Valley Urology ^*  (Canada)

^d Urology and Prostate Institute   (United States)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^f Erlanger Medical Center   (United States)

^g Cedar Associates LLC   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ SIMON FRASER UNIVERSITY   (Canada)

^j GenomeDx Biosciences Inc   (Canada)

more..

Author keywords

clinical practice; decision impact; metastasis; patient management; prognosis; prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CERTIFICATION; CLINICAL DECISION MAKING; CLINICAL OBSERVATION; CONTROLLED STUDY; GENETIC PROCEDURES; GENOMIC CLASSIFIER TEST; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL HISTORY; MEDICAL PRACTICE; METASTASIS POTENTIAL; MULTICENTER STUDY; PRACTICE GUIDELINE; PREDICTION; PROBABILITY; PROFESSIONAL KNOWLEDGE; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UROLOGIST; ALGORITHM; CLASSIFICATION; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DECISION MAKING; GENETICS; GENOMICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; UROLOGY;

ADULT; AGED; ALGORITHMS; DECISION MAKING; DIAGNOSIS, COMPUTER-ASSISTED; GENOMICS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; UROLOGY;

EID: 84922863245     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12789     Document Type: Article

References (26)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer Statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
2. Swanson GP, Riggs M, Hermans M,. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007; 25: 110-114
3. NCCN Clinical Guidelines in Oncology (NCCN Guideline). Prostate Cancer. Version 1. 2014 [Internet]. NCCN; 2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed January 2014
4. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578
5. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335
6. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930
7. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962
8. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-2027
9. Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline. J Urol 2013; 190: 441-449
10. Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol European Association of Urology; 2010 58: 687-700
11. Stephenson AJ, Kattan MW, Eastham J, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-4305
12. Sorensen KD, Orntoft TF,. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2010; 10: 49-64
13. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013; 8: e66855
14. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013; 190: 2047-2053
15. Den RD, Feng FY, Showalter TN, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. IJROBP 2014; 89: 1036-1044
16. Klein EA, Li J, Stephenson AJ, Yousefi K, Kattan MW, Magi-Galluzzi C,. Independent validation of a genomic classifier in an at risk population of men conservatively managed after radical prostatectomy. J Clin Oncol 2014; 32 (Suppl. 4): 16
17. Hornberger J, Doberne J, Chien R,. Laboratory-developed test-SynFRAME: an approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks. Genet Test Mol Biomarkers 2012; 16: 605-614
18. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14
19. Hornberger J,. Assigning value to medical algorithms: implications for personalized medicine. Per Med. 2013; 10: 577-588
20. Badani K, Thompson DJ, Buerki C, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013; 4: 600-609
21. R Development Core Team. R: A Language and Environment for Statistical Computing. [Internet]. Vienna, Austria: R Foundation for Statistical Computing, 2008. Available at: http://www.r-project.org. Accessed January 2014.
22. Association of Community Cancer Centers. [Internet]. 2014. [cited ]. Available at: http://www.accc-cancer.org/association/. Accessed January 2014.
23. Ghia AJ, Shrieve DC, Tward JD,. Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology 2010; 76: 1169-1174
24. Hoffman KE, Nguyen PL, Chen MH, et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 2011; 185: 116-120
25. Sheets NC, Hendrix LH, Allen IM, Chen RC,. Trends in the use of postprostatectomy therapies for patients with prostate cancer: a Surveillance, Epidemiology, and End Results Medicare analysis. Cancer 2013; 119: 3295-3301
26. Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2014; 17: 64-69